Qualcomm Stock's Pre-Earnings Technical Setup
Recently, QCOM's has been dismal. The stock finished all four of its next-day sessions lower over the past year, including an 8.9% drop in May. For this coming Thursday, the options pits are pricing in a 9% swing, regardless of direction, higher than the 6.3% move the stock has averaged over the last two years.
On the charts, Qualcomm stock has been running into pressure at the $162 level since early June. Support at the $153 level lingers below, however, as well as the 50-day moving average. Year-to-date, the equity is up 5.7%.
Notably, calls have been much more popular than usual over the past 10 weeks. QCOM's 50-day call/put volume ratio of 2.26 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks higher than 90% of readings from the past year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Stock Market Today: A Reprieve From Selling to Start the Week; Palantir Higher
Stock Market Today: A Reprieve From Selling to Start the Week; Palantir Higher originally appeared on TheStreet. Stocks have reclaimed just about all of their losses sustained in Friday's market slump. The big rally has not yet pushed the major indexes to record highs. At least not yet. A week or so ago, new 52-week highs were the daily norm for the Standard & Poor's 500 Index and the Nasdaq and Nasdaq-100 indexes. But the gains Monday are still impressive. At 1:55 p.m. EDT, the Standard & Poor's 500 Index was up 81 points, or 1.1%, to 6319, reclaiming 80% its Friday loss of 101 points. The Nasdaq Composite Index added 371 points, or 1.8%, to 21,026. And the Dow Jones Industrial Average jumped 492 points, or 1.1%, to 44,011 — not far from the index's Thursday close if 44,131.. At the same time, the crude oil was lower, down $1.05 to $66.28 a barrel. The 10-year Treasury yield was at 4.205%, down from Friday's 4.225%. Mortgage rates were moving lower. Mortgage News Daily's Monday survey put the rate on a 30-year mortgage at 6.57%, down from Friday's 6.63%. Tesla gives Elon Musk a big payday Tesla TSLA added 1.3% to $305.94 after the EV producer awarded CEO Elon Musk a $30 billion stock award to remain with the company for at least the next two years. Musk has said he wants a greater stake as he reorients Tesla to "around futuristic pursuits including artificial intelligence and driverless vehicles," Bloomberg News noted. In a letter to shareholders, the company said, "Tesla is transitioning from its role as a leader in the electric vehicle and renewable energy industries to grow towards becoming a leader in AI, robotics and related services. "To succeed, it requires a leader who combines strategic foresight, adaptability, and relentless execution to outperform competition and inspire the team." Updated: 10:55 a.m. ET It's always fun to remind folks of the wisdom of the late Gilda Radner's "Saturday Night Live" character Emily Litella. As in "Never mind." That seems to describe say how Wall Street is looking at last week's slide, especially Friday's ugly selloff. It's Monday, and the stock market has opened with a great big bang. At 10:15 a.m. EDT, the Standard & Poor's 500 Index was up 71 points, or 1.1%, to 6,309, reclaiming 70% its Friday loss of 101 points. The Nasdaq Composite Index added 322 points, or 1.6%, to 20,973. And the Dow Jones Industrial Average jumped 358 points, or 0.8%, to 43,946. Whether the gains hold for the rest of the day is another question. There are big earnings ahead, especially from Palantir () , which reports after today's close. Palantir is up 3.5% to $159.70, and it already hit a 52-week high of $160.92. Remember May and June? During those months, the S&P 500 would regularly gain or lose 1% in a day. After June 24 volatility dried up and the S&P 500 steadily marched higher. Stock traders said goodbye to July with a big reversal day -- a new high followed by a selloff that saw the benchmark index end nearly 0.4% lower. Not a big loss for the day, but it was an indication that things had changed. August came in like a lion, with traders selling stocks. The S&P 500 lost 1.6% and the tech-heavy Nasdaq dropped 2.2%. Big moves to end a July that had been up and to the right. What gives? The economy appears to be softening and unemployment is ticking higher. All while the S&P 500 is overvalued. As Stephen "Sarge" Guilfoyle reports over on TheStreet Pro, the Atlanta Fed revised its GDPNow model for Q3 down to 2.1% from 2.3%. The S&P 500 is trading at 22.2 times forward earnings, which is 10% above the five-year average. Stocks are priced for perfection. That said, earnings season, which is more than halfway over, has been a good one so far: 82% of S&P 500 constituents have beaten earnings estimates and 79% have topped revenue numbers. Year-over-year earnings growth is estimated at 10%. At the same time we're only beginning to see the impact of the Trump administration's tariffs. Our sister publication, Autoblog, yesterday reported that tariffs ate all of Ford's () profits for the second quarter. Ford will pay $3 billion to the U.S. government, despite its standing as "the most American automaker." GM () was hit with even higher tariffs, predicted to be $4 billion to $5 billion this year, causing a $1.1 billion loss in Q2. Ford makes around 80% of its cars in the U.S. but pays tariffs on imports of vehicle parts as well as steel and aluminum. Today, futures are indicating a bounce. The S&P 500 futures are up 0.6%, while Nasdaq futures are up 0.8%. Berkshire Hathaway () is trading 3% lower following a $3.8 billion impairment on its holdings of Kraft Heinz KHZ. The company's earnings were 31% below Wall Street expectations, on revenues that were in line with estimates. After the close, we'll hear from Palantir () . Analysts expect $0.14 EPS on revenue of $939 million. Shares were up 3.9% to $160.20 Stock Market Today: A Reprieve From Selling to Start the Week; Palantir Higher first appeared on TheStreet on Aug 4, 2025 This story was originally reported by TheStreet on Aug 4, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the 'CaRe PC' trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment. INKmune™ was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile, the primary endpoint of CaRe PC. Additionally, patients with low NK cell activation saw the greatest improvement in their biomarkers of NK cell activation, defining the target population for the next trials. 'INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease,' stated Dr. Mark Lowdell, CSO at INmune Bio. 'Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing.' Following the successful completion of the Phase 1/2 trial of INKmune™ in patients with advanced-stage disease, INmune Bio plans to advance the program by designing a randomized Phase 2b trial in patients with less severe disease, enabling a more robust measurement of the drug's effects and potential clinical benefits. About INKmune™ INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer patient's resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment converts the patient's own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells have persisted for more than 100 days. These cells function in the hypoxic TME because due to upregulated nutrient receptors and mitochondrial survival proteins. INKmune™ is a patient friendly drug treatment that does not require pre-medication, conditioning or additional cytokine therapy to be given to the patients. INKmune™ is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio's product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss Co-founder and Chief Financial Officer (858) 964-3720 info@ Daniel Carlson Head of Investor Relations (415) 509-4590 dcarlson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Take-Two Interactive Stock Is Beating the Market in 2025. Could a New Game Release Next Year Propel It to Even Greater Heights?
Key Points Investors have high expectations for next year's release in the bestselling Grand Theft Auto series. New game releases always pose a risk, but Take-Two has demonstrated a long history of profitably growing its business. Analysts expect the company's free cash flow to reach $2.9 billion by 2029. 10 stocks we like better than Take-Two Interactive Software › Take-Two Interactive (NASDAQ: TTWO) is on a roll as it prepares to launch a major new title that could bolster its growth prospects. It reported solid financial results for fiscal 2025 ending in March and expects record revenue for fiscal 2026. The stock is up about 21% year to date, outperforming the Nasdaq Composite's return of 10% at the time of writing. Investors are looking ahead to the highly anticipated release of Grand Theft Auto VI (GTA VI) on May 26, 2026. This release will land in the company's fiscal year 2027, where Wall Street analysts are already projecting a significant increase in revenue. What does this release mean for the stock, and can investors still expect the stock to move higher? Take-Two's profitable growth strategy While new releases in video games have inherent risks with player reception, this risk is relatively low for Take-Two. GTA has an established player base that is very passionate about the series. The last one significantly expanded the player base, selling 215 million copies over the last 12 years since its initial release. Take-Two is also investing to grow the business more broadly beyond reliance on GTA. It has significantly increased research and development (R&D) spending and headcount to prepare for several new releases in the coming years. Another factor that lowers the risk for Take-Two is that most of its revenue doesn't come from single-game sales but from ongoing spending by players throughout the year. In the most recent quarter, 77% of its bookings, which is non-GAAP (adjusted) revenue, came from recurrent consumer spending, which includes sales of virtual currency and subscription services that provide access to other content. Overall, last quarter's sales were driven by the usual suspects -- NBA 2K25, Grand Theft Auto V, Civilization VII, several mobile titles including Toon Blast, Red Dead Redemption 2, and WWE 2K25. While spending on R&D and integration of its acquisition of mobile game maker Zynga have weighed on margins and free cash flow the past few years, Take-Two's growth in recurrent consumer spending has dramatically improved its profitability over the last decade, pushing its stock price to new highs. The release of GTA VI and other titles in its pipeline is designed to scale the company's costs over more games, and, therefore, continue to grow margins and free cash flow over the long term. The stock can outperform the market I believe Take-Two is one of the best video game stocks to invest in right now because of these catalysts. The stock's valuation relative to growth expectations could support market-beating returns over the next few years. On a forward enterprise value (EV)-to-revenue basis, the stock trades at a 7.15x multiple -- lower than Roblox's 14.8x, and higher than Electronic Arts' 5.0x multiple. Microsoft paid a 7.44x EV-to-revenue multiple for Activision Blizzard a few years ago. Take-Two sits in the middle of the pack, which means it is fairly valued. These companies generate higher free cash flow than Take-Two, so investors are expecting Take-Two to improve its margins following the release of GTA VI. Long term, investors should expect leading game makers to adopt artificial intelligence (AI) to improve efficiency and automate more coding to lower costs. AI can reduce the time it takes to enter code and build games, which is a catalyst to watch for Take-Two's profitability over the next 10 years. Overall, the stock seems reasonably priced. With analysts expecting earnings to grow at an annualized rate of 39% through 2029, and free cash flow expected to reach $2.9 billion, the stock is likely to follow that growth. This sets up the likelihood that the stock can outperform the market from here. Should you buy stock in Take-Two Interactive Software right now? Before you buy stock in Take-Two Interactive Software, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Take-Two Interactive Software wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft, Roblox, and Take-Two Interactive Software. The Motley Fool recommends Electronic Arts and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Take-Two Interactive Stock Is Beating the Market in 2025. Could a New Game Release Next Year Propel It to Even Greater Heights? was originally published by The Motley Fool Sign in to access your portfolio
